Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyowa Hakko Kirin Co. Ltd.

Division of Kirin Holdings Co. Ltd.
www.kyowa-kirin.co.jp

Latest From Kyowa Hakko Kirin Co. Ltd.

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO

In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.

Business Strategies Commercial

Vadadustat Emerges As Japan HIF-PHI Leader With First Filing Globally

Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.

Japan Commercial

Positive Results Move Anemia Contender Enarodustat Towards First Filing

Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.

Japan Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register